Compare Stocks: HUM, LLY, DXCM, and JNJ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$89.65 -0.1%	$76.08	$54.11 ▼ $91.96	$33.83B	1.41	5.26 million shs	2,770 shs
HUM Humana	$381.74 -1.9%	$382.02	$163.11 ▼ $428.88	$46.19B	0.72	1.39 million shs	761,075 shs
JNJ Johnson & Johnson	$259.55 -0.3%	$251.92	$173.33 ▼ $274.90	$623.14B	0.24	8.25 million shs	10,098 shs
LLY Eli Lilly and Company	$1,175.68 -0.4%	$1,170.82	$685.15 ▼ $1,249.45	$1.10T	0.51	3.10 million shs	19,599 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	+5.90%	+17.09%	+37.89%	+10.87%
HUM Humana	0.00%	+0.97%	-3.08%	+27.02%	+35.38%
JNJ Johnson & Johnson	0.00%	+0.55%	+2.97%	+13.83%	+47.34%
LLY Eli Lilly and Company	0.00%	-0.38%	+0.36%	+19.57%	+68.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$89.65 -0.1%	$76.08	$54.11 ▼ $91.96	$33.83B	1.41	5.26 million shs	2,770 shs
HUM Humana	$381.74 -1.9%	$382.02	$163.11 ▼ $428.88	$46.19B	0.72	1.39 million shs	761,075 shs
JNJ Johnson & Johnson	$259.55 -0.3%	$251.92	$173.33 ▼ $274.90	$623.14B	0.24	8.25 million shs	10,098 shs
LLY Eli Lilly and Company	$1,175.68 -0.4%	$1,170.82	$685.15 ▼ $1,249.45	$1.10T	0.51	3.10 million shs	19,599 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	+5.90%	+17.09%	+37.89%	+10.87%
HUM Humana	0.00%	+0.97%	-3.08%	+27.02%	+35.38%
JNJ Johnson & Johnson	0.00%	+0.55%	+2.97%	+13.83%	+47.34%
LLY Eli Lilly and Company	0.00%	-0.38%	+0.36%	+19.57%	+68.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.89	Moderate Buy	$88.71	-1.05% Downside
HUM Humana	2.43	Hold	$395.22	3.53% Upside
JNJ Johnson & Johnson	2.80	Moderate Buy	$268.22	3.34% Upside
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	9.91% Upside

Current Analyst Ratings Breakdown

Latest HUM, LLY, DXCM, and JNJ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	DXCM DexCom	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/11/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	HUM Humana	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	HUM Humana	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$316.00 ➝ $393.00
8/7/2026	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,376.00
8/7/2026	LLY Eli Lilly and Company	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,370.00 ➝ $1,376.00
8/6/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$1,419.00
8/6/2026	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$270.00 ➝ $287.00
8/6/2026	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,280.00 ➝ $1,330.00
8/6/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,400.00
8/6/2026	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,350.00 ➝ $1,410.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.66B	7.26	$2.77 per share	32.41	$7.04 per share	12.73
HUM Humana	$129.66B	0.35	$23.61 per share	16.17	$147.47 per share	2.59
JNJ Johnson & Johnson	$94.19B	6.64	$14.08 per share	18.44	$33.85 per share	7.67
LLY Eli Lilly and Company	$65.18B	16.98	$25.04 per share	46.95	$28.07 per share	41.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$836.30M	$2.53	35.43	29.11	1.51	20.12%	35.94%	14.75%	10/29/2026 (Estimated)
HUM Humana	$1.19B	$10.57	36.39	25.21	2.23	0.88%	11.20%	3.94%	11/4/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.63	29.96	20.28	2.48	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	39.30	25.63	1.39	33.53%	97.83%	23.23%	10/29/2026 (Estimated)

Latest HUM, LLY, DXCM, and JNJ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
7/30/2026	Q2 2026	DXCM DexCom	$0.6110	$0.70	+$0.0890	$0.64	$1.29 billion	$1.31 billion
7/29/2026	Q2 2026	HUM Humana	$7.27	$7.61	+$0.34	$5.73	$40.58 billion	$40.89 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
HUM Humana	$3.54	0.93%	+7.20%	33.49%	N/A
JNJ Johnson & Johnson	$5.36	2.07%	+5.25%	62.11%	64 Years
LLY Eli Lilly and Company	$6.92	0.59%	+15.18%	23.22%	11 Years

Latest HUM, LLY, DXCM, and JNJ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.17%	8/25/2026	8/25/2026	9/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.47	1.73	1.43
HUM Humana	0.62	1.74	1.74
JNJ Johnson & Johnson	0.44	1.09	0.81
LLY Eli Lilly and Company	1.41	1.35	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
HUM Humana	92.38%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.28%
HUM Humana	0.20%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	11,000	377.36 million	376.30 million	Optionable
HUM Humana	67,060	120.08 million	119.84 million	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable

HUM, LLY, DXCM, and JNJ Headlines

Recent News About These Companies

Why Is Omniab Stock Rallying After Eli Lilly Deal?

5 minutes ago | benzinga.com

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer

49 minutes ago | finance.yahoo.com

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

49 minutes ago | finance.yahoo.com

OmniAb boosts 2026 cash outlook following Eli Lilly deal

2 hours ago | seekingalpha.com

Willis Investment Counsel Purchases 3,240 Shares of Eli Lilly and Company $LLY

2 hours ago | marketbeat.com

2,260 Shares in Eli Lilly and Company $LLY Acquired by Meridian Management Co.

4 hours ago | marketbeat.com

Heritage Investors Management Corp Grows Stake in Eli Lilly and Company $LLY

4 hours ago | marketbeat.com

TD Asset Management Inc Decreases Stock Position in Eli Lilly and Company $LLY

4 hours ago | marketbeat.com

Eli Lilly and Company $LLY Shares Acquired by Strive Financial Group LLC

4 hours ago | marketbeat.com

Eli Lilly and Company $LLY is Suncoast Equity Management's 5th Largest Position

4 hours ago | marketbeat.com

Qsemble Capital Management LP Trims Stock Position in Eli Lilly and Company $LLY

4 hours ago | marketbeat.com

Eli Lilly and Company $LLY Position Lowered by Chilton Capital Management LLC

August 17 at 3:51 AM | marketbeat.com

Gateway Wealth Partners LLC Has $3.15 Million Stock Holdings in Eli Lilly and Company $LLY

August 17 at 3:51 AM | marketbeat.com

Eli Lilly and Company $LLY Shares Bought by BCGM Wealth Management LLC

August 17 at 3:28 AM | marketbeat.com

Ascent Group LLC Purchases 1,544 Shares of Eli Lilly and Company $LLY

August 17 at 3:12 AM | marketbeat.com

Pharmaceutical Stocks To Watch Today - August 16th

August 16 at 2:01 PM | marketbeat.com

Best Healthcare Stocks To Follow Today - August 16th

August 16 at 1:00 PM | marketbeat.com

Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters

August 16 at 7:31 AM | insidermonkey.com

Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters

August 16 at 7:08 AM | finance.yahoo.com

TCW Group Inc. Acquires 2,913 Shares of Eli Lilly and Company $LLY

August 16 at 5:59 AM | marketbeat.com

Eli Lilly and Company $LLY Shares Purchased by SWS Partners

August 16 at 5:59 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HUM, LLY, DXCM, and JNJ Company Descriptions

DexCom NASDAQ:DXCM

$89.65 -0.10 (-0.12%)

As of 09:36 AM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Humana NYSE:HUM

$381.74 -7.31 (-1.88%)

As of 09:36 AM Eastern

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Johnson & Johnson NYSE:JNJ

$259.55 -0.80 (-0.31%)

As of 09:36 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$1,175.68 -4.48 (-0.38%)

As of 09:36 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HUM, LLY, DXCM, and JNJ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HUM, LLY, DXCM, and JNJ Earnings

Compare Dividends

Latest HUM, LLY, DXCM, and JNJ Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HUM, LLY, DXCM, and JNJ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HUM, LLY, DXCM, and JNJ Company Descriptions

DexCom NASDAQ:DXCM

Humana NYSE:HUM

Johnson & Johnson NYSE:JNJ

Eli Lilly and Company NYSE:LLY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools